1693PEfficacy and safety of anlotinib in advanced leiomyosarcoma: Subgroup analysis of a phase IIB trial (ALTER0203)

ConclusionsAnlotinib not only improves PFS and DCR significantly, but also presents good safety in patients with LMS, which suggests that anlotinib could be an option for LMS patients.Clinical trial identificationNCT02449343.Legal entity responsible for the studyChia Tai Tianqing Pharmaceutical Group Co., Ltd.FundingChia Tai Tianqing Pharmaceutical Group Co., Ltd.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research